Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies

Similar Items

• FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
  by: Mark C. Genovese, et al.
  Published: (2019-12-01)
• Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
  by: Stefan Schreiber, et al.
  Published: (2020-06-01)
• Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
  by: Roy M. Fleischmann, et al.
  Published: (2021-09-01)
• A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
  by: Roy M. Fleischmann, et al.
  Published: (2018-08-01)
• A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects
  by: Jim Bush, et al.
  Published: (2019-12-01)